medicina61巻1号

2024年01月発行

特集 その知見は臨床を変える?—エキスパートが解説! 内科における最新論文 呼吸器

気管支喘息治療の最新トピック

著者： 丸毛聡¹

所属機関： ¹公益財団法人田附興風会医学研究所北野病院呼吸器センター

ページ範囲：P.18 - P.23

Point
◎重症喘息のコントロールは2型炎症を制御する生物学的製剤の登場で大幅に改善したが，非2型炎症を呈する重症喘息への治療戦略はなく，アンメットニーズである．
◎抗TSLP抗体であるテゼペルマブは，幅広い抗炎症効果と気道過敏性改善効果を有し，2型炎症を呈する重症喘息に高い有効性を示すだけでなく，非2型炎症を呈するタイプにも有効である．
◎テゼペルマブを含めた生物学的製剤により重症喘息の治療はさらに高いレベルを求めることができ，今後は臨床的寛解・完全寛解が課題となる．

参考文献

1）Brusselle G, Bracke K：Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc 11 Suppl 5：S322-328, 2014 PMID 25525740

2）Gauvreau GM, et al：Thymic stromal lymphopoietin；Its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets 24：777-792, 2020 PMID 32567399

3）Kabata H, et al：Thymic stromal lymphopoietin induces corticosteroid resistance in natural helper cells during airway inflammation. Nat Commun 4：2675, 2013 PMID 24157859

4）Gauvreau GM, et al：Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 370：2102-2110, 2014 PMID 24846652

5）Diver S, et al：Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma（CASCADE）；A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 9：1299-1312, 2021 PMID 34256031

6）Corren J, et al：Tezepelumab in adults with uncontrolled asthma. N Engl J Med 377：936-946, 2017 PMID 28877011

7）Menzies-Gow A, et al：Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med 384：1800-1809, 2021 PMID 33979488

8）Wechsle ME, et al：Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma（SOURCE）；A randomised, placebo-controlled, phase 3 study. Lancet Respir Med 10：650-660, 2022 PMID 35364018

9）Shinkai M, et al：One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma；Results of the NOZOMI study. J Asthma 60：616-624, 2023 PMID 35707873

10）Menzies-Gow A, et al：Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma（DESTINATION）；A randomised, placebo-controlled extension study. Lancet Respir Med 11：425-438, 2023 PMID 36702146

11）Menzies-Gow A, et al：Tezepelumab compared with other biologics for the treatment of severe asthma；A systematic review and indirect treatment comparison. J Med Econ 25：679-690, 2022 PMID 35570578

12）Ando K, et al：Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers；A systematic review and network meta-analysis. Cells 11：819, 2022 PMID 35269440

13）Nopsopon T, et al：Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma；A Bayesian network meta-analysis. J Allergy Clin Immunol 151：747-755, 2023 PMID 36538979